NAD+ (nicotinamide adenine dinucleotide) is the longevity industry's current favorite molecule. IV NAD+ infusions cost $400 to $1,500 per session. NMN and NR supplements are a multi-billion-dollar market. And now "NAD+ peptides" — compounds that allegedly support NAD+ biosynthesis or mimic its effects — have entered the biohacking stack. Here is what the evidence for each intervention actually shows, stripped of the marketing.

Why NAD+ Matters (The Biology Is Real)

NAD+ is a coenzyme involved in hundreds of metabolic reactions and is essential for mitochondrial energy production, DNA repair, and the function of sirtuins — a class of proteins associated with longevity in multiple model organisms. NAD+ levels decline with age in human tissue: studies measuring NAD+ in blood and tissue biopsies consistently show 40-60% lower levels in older adults compared to younger ones.

This decline is real and well-documented. The question is whether restoring NAD+ levels through supplementation produces meaningful health or longevity outcomes in humans — and whether IV infusion versus oral precursors versus peptide approaches meaningfully differ in efficacy.

The Precursor Approach: NMN and NR

The most studied NAD+ precursors are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are orally bioavailable compounds that enter NAD+ biosynthetic pathways and raise blood NAD+ levels. Multiple human trials have confirmed this pharmacokinetic effect: oral NMN and NR do increase measurable NAD+ levels in blood and some tissues.

The harder question is what raising those levels does. A 2021 study in older adults found NMN supplementation increased muscle NAD+ levels and improved some measures of muscle function and insulin sensitivity. A 2022 trial found NR improved NAD+ levels but did not significantly improve cardiometabolic outcomes in obese adults over 12 weeks. Several other trials show NAD+ precursors affect various biomarkers; none have shown extended lifespan or dramatic functional improvements in humans.

The honest summary for oral NMN/NR: they raise NAD+ levels in humans (established), they affect some metabolic biomarkers (modest evidence), and they produce meaningful health or longevity outcomes (not established in well-powered trials). The supplement market has outrun the evidence substantially.

IV NAD+: Does It Work Differently?

IV NAD+ infusions bypass the gut and deliver NAD+ directly into the bloodstream. Proponents claim this achieves higher and faster tissue concentrations than oral precursors. The pharmacokinetic case is somewhat reasonable: IV delivery does produce rapid and large increases in blood NAD+, and some evidence suggests it penetrates specific tissues more effectively than oral precursors in certain contexts.

The evidence for IV NAD+ in humans is thin and largely anecdotal. The most robust use cases for IV NAD+ in existing medical literature involve addiction medicine — specifically, some clinics have reported that high-dose IV NAD+ reduces withdrawal symptoms and cravings in opioid and alcohol dependence, with some small published case series and one or two small controlled studies supporting this specific application. This is plausible biologically: NAD+ depletion in addiction is documented, and restoring levels during withdrawal addresses a real physiological deficit.

For the longevity and general wellness claims — energy, cognitive function, anti-aging — IV NAD+ has essentially no controlled trial data. The anecdotal reports are compelling (many people feel better immediately after infusions), but acute subjective wellbeing improvement is one of the most placebo-responsive outcomes in medicine. The IV administration context, the clinic setting, the staff attention, and the expectation of benefit all generate the conditions for strong placebo effects. That doesn't mean the effect isn't real — it means it's impossible to determine whether it's real without controls, which IV NAD+ clinics do not provide.

NAD+ Peptides: The Newest Layer

The category of "NAD+ peptides" is less well-defined than oral precursors or IV infusions. It generally refers to one of two things: peptides that allegedly support NAD+ biosynthesis pathways (by modulating enzymes in the NAD+ salvage or de novo synthesis pathways), or compounds like MOTS-c and humanin that are mitochondrial-derived peptides with effects that overlap with NAD+-related pathways.

MOTS-c is a peptide encoded by mitochondrial DNA (a notable distinction — most peptides are nuclear-encoded) that activates AMPK and affects glucose metabolism. Mouse studies show MOTS-c injection reduces obesity and improves metabolic parameters. It interacts with NAD+-related pathways including sirtuins. Human studies: essentially none. MOTS-c is being marketed as an NAD+-adjacent longevity peptide without any human trial evidence.

5-amino-1MQ is a small molecule (not technically a peptide, though often marketed alongside peptides) that inhibits NNMT, an enzyme that consumes methyl groups that would otherwise support NAD+ synthesis. The theoretical effect is to support NAD+ levels by reducing consumption. Mouse data shows fat loss and metabolic improvement. Human data: none published.

These compounds share the same fundamental limitation: interesting mechanism, mouse data, zero human trial evidence, and marketing that presents them as established interventions. The same evidence-to-claim gap that characterizes other longevity peptides applies here.

The Honest Comparison

Stacking these up by evidence quality:

  • Oral NMN/NR: Best-evidenced category. Bioavailability confirmed, NAD+ elevation confirmed, some metabolic effects in small trials. No established longevity benefit in humans. Reasonable cost ($30-100/month). Most defensible option for someone who wants to experiment with NAD+ supplementation.
  • IV NAD+: Strong acute physiological effect. Plausible for specific applications (addiction medicine). No controlled evidence for general longevity or wellness claims. Very high cost ($400-1,500/session). Compelling anecdote, essentially no controlled human data for most use cases.
  • NAD+ peptides (MOTS-c, 5-amino-1MQ): Interesting mechanisms, mouse data, zero human trials. Gray-market sourcing only. No established safety profile in humans. Lowest evidence tier in the comparison, often highest per-dose cost.

What Would Actually Change This Picture

NAD+ biology is a legitimate and active area of research. Several academic groups are conducting trials with NMN and NR in aging populations, and the NAD+ World Conference has documented some compelling animal lifespan data. This is not pseudoscience. The mechanisms are real, the age-related decline is real, and the question of whether supplementation helps in humans is genuinely open.

What would change the picture: large, adequately powered, randomized controlled trials with lifespan or healthspan primary endpoints. Several are underway. Until results are available, the longevity claims being made for any NAD+-related intervention in humans — IV, oral, or peptide — outrun the evidence by a significant margin.

Bottom Line

The NAD+ decline-with-age story is real. The evidence that any specific intervention reverses meaningful aging outcomes in humans is not established. Oral NMN/NR is the most cost-effective and best-evidenced option for someone who wants to experiment. IV NAD+ has specific applications (addiction) and compelling anecdote for general wellness with no controlled backing. NAD+ peptides are the latest iteration of the same pattern: interesting preclinical data, zero human trials, premium pricing.

Before spending on any longevity intervention, score the specific claim you're being sold — not "NAD+ supports cellular health" (too vague to score) but the actual promise: "X intervention will produce Y outcome." That precision is where the evidence gap usually reveals itself.